Skip to main content

ERRATUM article

Front. Immunol., 20 August 2021
Sec. Vaccines and Molecular Therapeutics
Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.754535

Erratum: Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components

This article is an erratum on:

  1. Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An erratum on
Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components

By Hernandez-Davies JE, Felgner J, Strohmeier S, Pone EJ, Jain A, Jan S, Nakajima R, Jasinskas A, Strahsburger E, Krammer F, Felgner PL and Davies DH (2021). Front. Immunol. 12:692151. doi: 10.3389/fimmu.2021.692151

Due to a production error, there was a mistake in Figure 6 as published. Part of the y axis title and scale in Figure 6B was obscured by a white area.

The corrected Figure 6 appears below. The publisher apologizes for this mistake.

FIGURE 6
www.frontiersin.org

Figure 6 Boosting is required to generate virus neutralization after receiving trivalent vaccine. (A) Means of signals at different time points for HA0 and HA1 variants of H1, H5 and H7 after administration of trivalent vaccine. (B) HI assay titers of individual sera used in panels (A, B) against PR8 reassortant influenza viruses expressing Cal09 H1, VN04 H5 and AH13 H7, respectively. Horizontal dotted line, 1/40 dilution cutoff (log-2 of 40 = 5.32) (C) serial dilutions of plasma from a representative mouse to determine titers at different time points using microarrays; shown are means of H1, H5 and H7 variants after serial dilutions. All data are representative of two separate experiments. PB1, post first boost; PB2, post second boost; red arrows, boosts. ****P < 0.0001; ***P ≤ 0.001; **P ≤ 0.01; *P < 0.05.

The original version of this article has been updated.

Keywords: vaccine, influenza, adjuvant, CpG, MPLA, ADDAVAX®, hemagglutinin

Citation: Frontiers Production Office (2021) Erratum: Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components. Front. Immunol. 12:754535. doi: 10.3389/fimmu.2021.754535

Received: 06 August 2021; Accepted: 06 August 2021;
Published: 20 August 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.